Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies.
Denise ObrechtMartin MynarekChristian HagelRobert KwiecienMichael SpohnMichael BockmayrBrigitte BisonStefan M PfisterDavid T W JonesDominik SturmAndreas von DeimlingFelix SahmKatja von HoffB-Ole JuhnkeMartin BeneschNicolas U GerberCarsten FriedrichAndré O von BuerenRolf-Dieter KortmannRudolf SchwarzTorsten PietschGudrun FleischhackUlrich SchüllerStefan RutkowskiPublished in: Journal of neuro-oncology (2022)
Our results confirm that M1-only is a high-risk condition, and further underline the importance of CSF staging. Specific risk stratification of affected patients needs attention in future discussions for trials and treatment recommendations. Future patients without contraindications may benefit from upfront CSI by sparing risks related to higher cumulative CT applied in sandwich regimen.